相关临床试验
102
15 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1865
进行中（未招募）
8
7.8%
已完成
75
73.5%
Enrolling By Invitation
2
2.0%
尚未招募
5
4.9%
招募中
9
8.8%
终止
1
1.0%
Unknown
2
2.0%
暂无批准数据
- Cornell University researchers discovered that fibrolamellar carcinoma tumors sequester immune T cells away from cancer cells, explaining why immunotherapy fails in this rare liver cancer. - The FDA-approved drug AMD3100 successfully mobilized T cells into tumor cores and enhanced immune checkpoint inhibitor effectiveness in patient tumor samples. - The combination treatment led to significant increases in tumor cell death, offering new hope for fibrolamellar carcinoma patients who currently have no cure. - Researchers are now seeking clinicians to initiate clinical trials, with AMD3100's existing FDA approval potentially accelerating the development timeline.
- Cornell researchers discovered that ultrasmall silica nanoparticles called C'dots can reprogram immune-resistant tumor microenvironments, transforming "cold" tumors into "hot" ones that respond better to immunotherapy. - The nanoparticles activate multiple anti-tumor mechanisms simultaneously, including stimulating innate immune responses, inducing cell-cycle arrest, and reprogramming T cells and macrophages to attack cancer more effectively. - In mouse models, combining C'dots with immunotherapies targeting immune checkpoints and cytokines led to significant survival advantages compared to immunotherapy alone. - The approach shows promise beyond melanoma, with similar immune-activating effects observed in prostate and ovarian cancer models, suggesting broad therapeutic potential.
- Renerva Inc received FDA Investigational Device Exemption approval to begin first-in-human clinical trials of its PNM-CAP nerve capping device at The Ohio State University Wexner Medical Center. - The device is designed to prevent neuroma formation and chronic pain following nerve transection during amputation procedures, addressing a critical unmet need for over 2 million US amputees. - Preclinical studies published in npj Regenerative Medicine demonstrated up to 16-fold reduction in nerve growth and 3.5-fold reduction in pain behavior compared to standard care controls. - The clinical trial will enroll 10 patients over one year to evaluate the device's ability to reduce pain, limit opioid consumption, and improve quality of life for amputation patients.
- Cornell University and Akston have initiated a clinical trial of AKS-562c, a once-weekly GLP-1 Fc-fusion therapy for weight management in client-owned cats with excess body condition. - Okava Pharmaceuticals has launched MEOW-1, the first clinical trial using a miniature GLP-1 implant (OKV-119) that delivers continuous therapy for up to six months in overweight cats. - Both trials address a significant unmet medical need, as 61% of US cats were classified as overweight or obese in 2022, with obese cats being 7 times more likely to develop diabetes. - The competing approaches represent different dosing strategies for GLP-1 therapy in felines, with Akston targeting weekly injections and Okava developing long-acting implants for sustained drug delivery.
- Researchers at the University of East Anglia developed the first blood-based diagnostic test for ME/CFS using epigenetic markers, achieving 96% accuracy with 92% sensitivity and 98% specificity in distinguishing severe patients from healthy controls. - The EpiSwitch® CFS test analyzes 3D chromosomal conformations in blood cells and identified 200 key biomarkers distributed across multiple chromosomes, suggesting ME/CFS involves complex genomic dysregulation rather than single-gene defects. - Pathway analysis revealed the epigenetic signatures strongly correlate with immune dysfunction, particularly IL-2 signaling pathways, and showed overlap with therapeutic targets for rituximab and copaxone, potentially enabling personalized treatment approaches. - The test represents a significant advancement over existing diagnostic approaches that rely solely on clinical criteria, offering hope for earlier diagnosis and better management of the 17-24 million people worldwide affected by this debilitating condition.
- Cornell researchers have bioengineered bacteria with a unique enzyme from Desulfovibrio marinus to attach glycans to monoclonal antibodies, potentially democratizing access to therapeutic antibody drugs. - The breakthrough addresses a key limitation of bacterial production systems by enabling protein glycosylation, which impacts over 50% of human proteins and is critical for antibody immune function. - The engineered E. coli bacteria could offer dramatically accelerated production speeds and significantly lower costs compared to conventional Chinese hamster ovary cell manufacturing methods. - The technology could enable production of antibody drugs for cancer, autoimmune, and infectious diseases, though optimization for higher production titers remains necessary.
- Researchers at Sichuan University developed edible microbeads composed of green tea polyphenols, vitamin E, and alginate that trap dietary fats in the gastrointestinal tract to prevent absorption. - In a 30-day rat study, animals fed a high-fat diet with microbeads achieved 17% weight loss compared to controls, with reduced adipose tissue and liver damage markers. - The microbeads demonstrated superior tolerability compared to orlistat, showing no gastrointestinal side effects while achieving similar fat excretion levels. - Human clinical trials are underway with 26 participants to evaluate safety and efficacy, with preliminary results expected within the year.
- Cornell researchers have developed a new material that could significantly improve mRNA vaccine delivery and effectiveness by replacing ingredients that may trigger unwanted immune responses. - The innovation focuses on creating 'stealthy' lipid nanoparticles that enhance the therapeutic potential of mRNA vaccines like those used against COVID-19. - This breakthrough addresses a key challenge in mRNA vaccine technology by potentially reducing adverse immune reactions while maintaining vaccine efficacy.
- Biostate AI has raised $12 million in Series A funding led by Accel to develop affordable RNA sequencing technology and AI-powered diagnostic models. - The company's proprietary BIRT and PERD technologies reduce RNAseq costs by nearly an order of magnitude, enabling researchers to run 2-3 times more samples within existing budgets. - Founded by former professors David Zhang and Ashwin Gopinath, Biostate AI aims to build "foundation models" for molecular medicine by analyzing billions of RNA expressions to predict disease evolution and drug responses.
- Biostate AI and Weill Cornell Medicine have formed a strategic collaboration to develop AI models for personalized leukemia care, initially focusing on acute myeloid leukemia (AML) using RNA sequencing technology. - The partnership will analyze up to 50,000 retrospective bone marrow and blood samples to create AI models capable of AML subtype stratification, disease prognosis, and therapy selection for more precise treatment decisions. - The collaboration leverages Biostate AI's proprietary BIRT technology for RNA sequencing and Weill Cornell's extensive biorepository, aiming to improve patient outcomes through comprehensive transcriptomic analysis rather than limited biomarker approaches.
